Acuity Brands to Announce Fiscal 2024 Second Quarter Results on April 3, 2024
ATLANTA, March 06, 2024 (GLOBE NEWSWIRE) — Acuity Brands, Inc. (NYSE: AYI) (the “Company”) today announced that it is planning […]
IDT Corporation Reports Second Quarter Fiscal Year 2024 Results
GAAP EPS of $0.57 – unchanged YoY; Non-GAAP EPS*increased to $0.67 from $0.62 Cash, cash equivalents, debt securities, and current […]
Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, […]
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical […]
DraftKings Announces Jason Robins’ Participation in Upcoming Event
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) — DraftKings Inc. (Nasdaq: DKNG) (“DraftKings” or the “Company”) today announced that Jason Robins, […]
BioSyent Schedules Fourth Quarter and Full Year 2023 Earnings Release for March 13, 2024
MISSISSAUGA, Ontario, March 06, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its […]
Intrepid Announces Fourth Quarter and Full-Year 2023 Results
Denver, CO, March 06, 2024 (GLOBE NEWSWIRE) — Intrepid Potash, Inc. (NYSE:IPI) (“Intrepid”, the “Company”, “we”, “us” and “our”) [...]
Vigil Announces Oral Presentation on Small Molecule TREM2 Agonist VG-3927 as a Potential Disease-Modifying Therapeutic at AD/PD 2024
WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing […]
NL REPORTS FOURTH QUARTER 2023 RESULTS
Dallas, Texas, March 06, 2024 (GLOBE NEWSWIRE) — NL Industries, Inc. (NYSE: NL) today reported net income attributable to NL […]
Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
– Company is leveraging proprietary cell-targeted lipid nanoparticle delivery to develop wholly-owned in vivo program for sickle cell disease and […]
